APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 40 people and is led by a management team with strong background in drug development, especially in immuno-oncology.

Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and has achieved marketing authorization in the EU for immunotherapy of neuroblastoma in May 2017.
See projects for the present status of Apeiron's portfolio.

 Non-Confidential Company Presentation

  • 1451 hits08 January 2018

    APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance With Sanofi

    APEIRON Biologics AG and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015.



     Press Release